The earnings call highlights significant growth in revenue and prescription volume for Neffy, along with expanded global presence and commercial coverage. However, high SG&A expenses and ongoing challenges with prior authorization requirements present some concerns. The positive aspects of the call, particularly the strong revenue growth and strategic global expansion, outweigh the lowlights.

Company Guidance

During the ARS Pharmaceuticals conference call for the second quarter of 2025, the company provided guidance on several key metrics. The U.S. net product revenue for neffy reached $12.8 million, marking a 64% increase from the previous quarter, supported by the launch of the 1-milligram pediatric dose and improved payer coverage. Neffy prescriptions saw a significant rise, with a 180% increase in weekly two-pack unit volume from the end of Q1 to Q2 2025. The company achieved 93% commercial coverage, with approximately 57% of commercial payers not requiring prior authorizations (PAs). The direct-to-consumer (DTC) campaign, "Hello neffy, Goodbye Needles," has increased aided awareness to nearly 50% since its launch, while the physician engagement strategy reached approximately 15,000 healthcare providers. ARS Pharmaceuticals anticipates further growth in the third and fourth quarters, driven by ongoing consumer engagement, expanded reach from the ALK co-promotion, and the peak back-to-school season. Additionally, the company maintains a strong cash position with $240.1 million in cash, cash equivalents, and short-term investments, ensuring over three years of operating runway.

Neffy Revenue Growth

In Q2 2025, ARS Pharmaceuticals achieved $12.8 million in net product revenue for Neffy, reflecting a 64% increase compared to the first quarter of the year.

Increased Prescription Volume

From the end of Q1 to the end of Q2 2025, a 180% increase in weekly two-pack unit volume was observed for Neffy.

Expanded Coverage and Accessibility

Neffy has achieved 93% commercial coverage, with approximately 57% of commercial payers not requiring prior authorization.

Global Expansion

In June, Neffy was launched in Germany, and in July, it was approved in the UK. Regulatory decisions are expected in Canada, Australia, Japan, and China by 2026.

ARS Pharmaceuticals (SPRY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SPRY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.46 / -	-0.2	―	―	―
Aug 13, 2025	2025 (Q2)	-0.46 / -0.46	-0.13	-253.85% (-0.33)	―
May 14, 2025	2025 (Q1)	-0.34 / -0.35	-0.11	-218.18% (-0.24)	―
Mar 20, 2025	2024 (Q4)	-0.24 / 0.48	-0.07	785.71% (+0.55)	―
Nov 13, 2024	2024 (Q3)	-0.14 / -0.20	-0.16	-25.00% (-0.04)	―
Aug 06, 2024	2024 (Q2)	-0.11 / -0.13	-0.18	27.78% (+0.05)	―	―
May 09, 2024	2024 (Q1)	-0.10 / -0.11	-0.16	31.25% (+0.05)	―	―
Mar 21, 2024	2023 (Q4)	-0.14 / -0.07	-0.26	73.08% (+0.19)	―	―
Nov 09, 2023	2023 (Q3)	-0.18 / -0.16	-0.5	68.00% (+0.34)	―	―
Aug 10, 2023	2023 (Q2)	-0.17 / -0.18	-0.553	67.45% (+0.37)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SPRY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$16.66	$15.82	-5.04%
May 14, 2025	$13.35	$12.10	-9.36%
Mar 20, 2025	$11.65	$14.31	+22.83%
Nov 13, 2024	$16.61	$14.08	-15.23%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ars Pharmaceuticals, Inc. (SPRY) report earnings?

Ars Pharmaceuticals, Inc. (SPRY) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Ars Pharmaceuticals, Inc. (SPRY) earnings time?

Ars Pharmaceuticals, Inc. (SPRY) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SPRY EPS forecast?

SPRY EPS forecast for the fiscal quarter 2025 (Q3) is -0.46.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing